Corline Biomedical AB has signed a Letter of Intent with James Shapiro and The Clinical Islet Transplant Program at University of Alberta, an educational university, to evaluate a collaboration for clinical studies in type I diabetes. Under the agreement, Corline Biomedical transmits the technology for treating islet cells with Cytoparin and provides regulatory support, while The Clinical Islet Transplant Program at University of Alberta carries out the Cytoparin treatment of the islets, as well as recruits and treats patients within the framework for the clinical study. Corline Biomedical still retains all commercial rights attached to the product. Technology transfer and contacts with regulatory authorities are scheduled to start after the summer of 2017, when a formal agreement between the parties is expected to be in place. This agreement enables Corline Biomedical and University of Alberta to collaborate for clinical study in type 1 diabetes. This agreement enables Corline Biomedical and University of Alberta to collaborate for clinical study in type 1 diabetes.